Each of the BRD and HDAC inhibitors diminished breast cancer cell viability within a desirable molar range (0.008–0.5 μM), and led to further reduction in viability across all models tested when combined with standard of care (Fig 4E and F). Here, HDAC9 is linked to breast carcinoma.